Nuveen Asset Management LLC Trims Holdings in NeoGenomics, Inc. (NASDAQ:NEO)

Nuveen Asset Management LLC trimmed its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 22.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 345,667 shares of the medical research company's stock after selling 98,179 shares during the quarter. Nuveen Asset Management LLC owned approximately 0.27% of NeoGenomics worth $5,697,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in NEO. Blue Trust Inc. raised its position in shares of NeoGenomics by 33.2% during the fourth quarter. Blue Trust Inc. now owns 4,421 shares of the medical research company's stock worth $73,000 after acquiring an additional 1,103 shares during the last quarter. KBC Group NV grew its stake in NeoGenomics by 44.7% during the fourth quarter. KBC Group NV now owns 6,557 shares of the medical research company's stock worth $108,000 after purchasing an additional 2,027 shares during the period. Chicago Capital LLC acquired a new stake in NeoGenomics during the fourth quarter worth approximately $270,000. Jennison Associates LLC grew its stake in NeoGenomics by 18.7% during the fourth quarter. Jennison Associates LLC now owns 1,514,756 shares of the medical research company's stock worth $24,963,000 after purchasing an additional 238,288 shares during the period. Finally, Guidance Capital Inc. acquired a new stake in NeoGenomics during the fourth quarter worth approximately $528,000. 98.50% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently commented on NEO. Leerink Partners cut NeoGenomics from an "outperform" rating to a "market perform" rating and decreased their target price for the stock from $25.00 to $9.00 in a research note on Wednesday, April 30th. Guggenheim began coverage on NeoGenomics in a research note on Thursday, May 15th. They set a "neutral" rating for the company. Leerink Partnrs cut NeoGenomics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 30th. Needham & Company LLC decreased their target price on NeoGenomics from $18.00 to $8.50 and set a "buy" rating for the company in a research note on Tuesday, April 29th. Finally, Wall Street Zen raised NeoGenomics from a "sell" rating to a "hold" rating in a research note on Tuesday, May 13th. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $13.83.

Insider Activity

In other NeoGenomics news, CFO Jeffrey Scott Sherman purchased 20,000 shares of the company's stock in a transaction that occurred on Friday, May 2nd. The shares were acquired at an average cost of $7.51 per share, for a total transaction of $150,200.00. Following the completion of the acquisition, the chief financial officer now owns 158,494 shares of the company's stock, valued at $1,190,289.94. The trade was a 14.44% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Warren Stone purchased 5,700 shares of the company's stock in a transaction that occurred on Monday, May 12th. The shares were acquired at an average price of $8.58 per share, for a total transaction of $48,906.00. Following the completion of the acquisition, the chief operating officer now directly owns 108,280 shares of the company's stock, valued at $929,042.40. This trade represents a 5.56% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 70,600 shares of company stock worth $550,438 over the last 90 days. 2.40% of the stock is currently owned by corporate insiders.

NeoGenomics Stock Down 1.3%

Shares of NEO stock traded down $0.10 during trading hours on Wednesday, reaching $7.38. The company had a trading volume of 1,561,345 shares, compared to its average volume of 1,175,057. NeoGenomics, Inc. has a 12 month low of $6.08 and a 12 month high of $19.12. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.98 and a quick ratio of 1.91. The business has a fifty day simple moving average of $8.41 and a 200-day simple moving average of $12.21. The company has a market cap of $949.77 million, a price-to-earnings ratio of -11.90 and a beta of 1.60.

NeoGenomics (NASDAQ:NEO - Get Free Report) last posted its earnings results on Tuesday, April 29th. The medical research company reported ($0.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.06). NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. The company had revenue of $168.04 million during the quarter, compared to the consensus estimate of $171.38 million. During the same quarter in the prior year, the business earned ($0.02) EPS. The firm's revenue for the quarter was up 7.6% compared to the same quarter last year. On average, research analysts expect that NeoGenomics, Inc. will post -0.2 earnings per share for the current fiscal year.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.